<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">2985134R</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2913</journal-id>
<journal-id journal-id-type="nlm-ta">Chem Rev</journal-id>
<journal-id journal-id-type="iso-abbrev">Chem. Rev.</journal-id>
<journal-title-group>
<journal-title>Chemical reviews</journal-title>
</journal-title-group>
<issn pub-type="ppub">0009-2665</issn>
<issn pub-type="epub">1520-6890</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26882314</article-id>
<article-id pub-id-type="pmc">4988345</article-id>
<article-id pub-id-type="doi">10.1021/acs.chemrev.5b00656</article-id>
<article-id pub-id-type="manuscript">NIHMS808701</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lindsley</surname>
<given-names>Craig W.</given-names>
</name>
<xref ref-type="aff" rid="A1">†</xref>
<xref ref-type="aff" rid="A2">‡</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Emmitte</surname>
<given-names>Kyle A.</given-names>
</name>
<xref ref-type="aff" rid="A4">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hopkins</surname>
<given-names>Corey R.</given-names>
</name>
<xref ref-type="aff" rid="A1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bridges</surname>
<given-names>Thomas M.</given-names>
</name>
<xref ref-type="aff" rid="A1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gregory</surname>
<given-names>Karen J.</given-names>
</name>
<xref ref-type="aff" rid="A5">‖</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Niswender</surname>
<given-names>Colleen M.</given-names>
</name>
<xref ref-type="aff" rid="A1">†</xref>
<xref ref-type="aff" rid="A3">⊥</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conn</surname>
<given-names>P. Jeffrey</given-names>
</name>
<xref ref-type="aff" rid="A1">†</xref>
<xref ref-type="aff" rid="A3">⊥</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>†</label>Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States</aff>
<aff id="A2"><label>‡</label>Department of Chemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States</aff>
<aff id="A3"><label>⊥</label>Vanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States</aff>
<aff id="A4"><label>§</label>Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, Texas 76107, United States</aff>
<aff id="A5"><label>‖</label>Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville VIC 3052, Australia</aff>
<author-notes>
<corresp id="cor1"><label>*</label><bold>Corresponding Authors</bold>, <email>craig.lindsley@vanderbilt.edu</email>. <email>jeff.conn@vanderbilt.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>6</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>8</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>08</day>
<month>6</month>
<year>2017</year>
</pub-date>
<volume>116</volume>
<issue>11</issue>
<fpage>6707</fpage>
<lpage>6741</lpage>
<!--elocation-id from pubmed: 10.1021/acs.chemrev.5b00656-->
<abstract id="Abs1">
<p id="P1">Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery, filled with therapeutic promise yet fraught with caveats. Allosteric ligands stabilize unique conformations of the GPCR that afford fundamentally new receptors, capable of novel pharmacology, unprecedented subtype selectivity, and unique signal bias. This review provides a comprehensive overview of the basics of GPCR allosteric pharmacology, medicinal chemistry, drug metabolism, and validated approaches to address each of the major challenges and caveats. Then, the review narrows focus to highlight recent advances in the discovery of allosteric ligands for metabotropic glutamate receptor subtypes 1–5 and 7 (mGlu <sub>1–57</sub>) highlighting key concepts (“molecular switches”, signal bias, heterodimers) and practical solutions to enable the development of tool compounds and clinical candidates. The review closes with a section on late-breaking new advances with allosteric ligands for other GPCRs and emerging data for endogenous allosteric modulators.</p>
</abstract>
<abstract abstract-type="graphical" id="Abs2">
<title>Graphical Abstract</title>
<p id="P2">
<graphic orientation="portrait" position="anchor" xlink:href="nihms808701f28.jpg"></graphic>
</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>